Merck & Co., Inc. (NYSE:MRK) Downgraded to “Hold” Rating by Jefferies Financial Group

Merck & Co., Inc. (NYSE:MRK) was downgraded by research analysts at Jefferies Financial Group from a “strong-buy” rating to a “hold” rating in a research report issued on Wednesday,Zacks.com reports.

A number of other equities research analysts have also recently issued reports on the stock. Bank of America upped their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. CICC Research assumed coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price objective on the stock. Barclays boosted their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Finally, Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Fifteen analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $135.50.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $152.21 on Wednesday. The stock has a market capitalization of $375.53 billion, a P/E ratio of 121.77, a P/E/G ratio of 5.83 and a beta of 0.19. The business has a 50-day moving average of $126.86 and a two-hundred day moving average of $120.74. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $153.50. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm’s revenue was up 5.1% compared to the same quarter last year. During the same period last year, the business earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Richard R. Deluca sold 20,784 shares of Merck & Co., Inc. stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the sale, the executive vice president directly owned 134,703 shares of the company’s stock, valued at $17,569,312.29. This trade represents a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the transaction, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. This represents a 24.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last three months. Company insiders own 0.17% of the company’s stock.

Institutional Trading of Merck & Co., Inc.

Hedge funds have recently modified their holdings of the company. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $25,000. Abound Financial LLC bought a new position in Merck & Co., Inc. in the fourth quarter worth $26,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. in the fourth quarter worth $26,000. High Note Wealth LLC boosted its stake in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in Merck & Co., Inc. during the fourth quarter worth $31,000. Institutional investors own 76.07% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Phase 3 melanoma success: Moderna and Merck said their individualized mRNA vaccine, intismeran, combined with Merck’s Keytruda, met the primary endpoint in a large Phase 3 trial. The combination significantly extended recurrence-free survival and reduced the risk of melanoma spreading compared with Keytruda alone. This represents the first positive late-stage result for a personalized mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: New growth opportunity for Keytruda: The results could expand Merck’s oncology franchise by pairing Keytruda with a mutation-targeted vaccine. The companies believe thousands of high-risk melanoma patients could eventually benefit, pending regulatory approval targeted for 2027. Similar trials are underway in lung, pancreatic, breast and other cancers. Why this mRNA cancer vaccine is raising new treatment hope
• Positive Sentiment: Strategic importance before patent expiry: A successful vaccine-Keytruda combination could help support Merck’s oncology pipeline as Keytruda’s patent protection is expected to expire later this decade. Unusually heavy call-option activity also indicated heightened bullish trading interest.
• Neutral Sentiment: Broader market support: Relief in bond markets helped lift rate-sensitive healthcare stocks generally, providing an additional supportive backdrop for Merck’s move. However, the company’s advance was primarily tied to the vaccine announcement.
• Negative Sentiment: Important uncertainties remain: The companies released topline results, while investors and analysts await complete trial data. The vaccine still requires regulatory approval, and the commercial opportunity, pricing and longer-term benefits are not yet established. Merck also faces substantial future pressure from Keytruda’s eventual loss of exclusivity.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.